New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
09:29 EDTONCYOncolytics Biotech signs $25M share purchase agreement with Lincoln Park Capital
Oncolytics Biotech has entered into a share purchase agreement with Lincoln Park Capital Fund that will provide an initial investment in Oncolytics of $1.0M and make available additional periodic investments of up to $25.0M over a 30-month term. Oncolytics received a $1.0M investment in exchange for the issuance of 600,962 common shares to LPC at a per share purchase price of $1.664. In addition, Oncolytics may sell up to $25.0M worth of common shares to LPC over the 30-month term.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 18, 2015
06:41 EDTONCYOncolytics Biotech completes enrollment of randomized Phase II study of REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech completes enrollment in Phase II colorectal cancer study
Subscribe for More Information
February 17, 2015
06:40 EDTONCYOncolytics Biotech receives ODD from FDA for REOLYSIN
Subscribe for More Information
06:36 EDTONCYOncolytics Biotech granted Orphan Drug Designation for REOLYSIN by FDA
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. REOLYSIN is Oncolytics' proprietary isolate of the reovirus. Its primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF and KRAS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use